Global Health Updates: Pharma Tariffs, RSV Vaccine Approval, and Infant Formula Insights

Recent health news highlights include Recordati's nonchalance towards potential U.S. tariffs, Canada's approval of Moderna's RSV vaccine for seniors, the FDA's stance against phenylephrine, France's heightened avian flu risk, and the UK's CMA's recommendations for better baby formula distribution practices to assist parents.

In a world where tariffs can shake markets, Italian drug maker Recordati remains unfazed by potential U.S. pharmaceutical tariffs under President-elect Donald Trump, the CFO stated, emphasizing no anticipated impact on their rare diseases sector.

In a breakthrough for senior health, Canada's regulators approved Moderna's RSV vaccine for adults over 60, marking the nation's first mRNA-based solution against respiratory syncytial virus. Moderna plans supply by early 2025.

The U.S. FDA has proposed eliminating phenylephrine from over-the-counter medications, citing inefficacy. This move could see famous brands like Benadryl, Advil, and Tylenol re-evaluating their formulations.

France, reacting to a spike in EU bird flu cases, has elevated its alert level to high. This measure aims to fortify protections around poultry farms amid fears of potential human transmission.

The UK's Competition and Markets Authority has raised concerns about infant formula distribution, advocating for better packaging standardization and transparent nutritional labeling to support parental decision-making.

(With inputs from agencies.)